The April and YTD performances of the psychedelic drug stocks we track in our index, vary pretty widely from company to company, but almost universally are expected to rise substantially.

The munKNEE Psychedelic Drug Stocks Index was down 3.4% in March but is still +1.2% YTD. The best news is the continuing high price targets being set by analysts.

The progress Seelos is achieving in its multi-faceted clinical trials has investors taking a long hard look at what it's all about.

The most critical financial information on the health of a company is whether, or not, it has a Net Positive Operating Cash Flow; its Altman -Z Score; its Piotroski F-Score; and the percentage likelihood of it going bankrupt within the next 2 years.

Cannabis, psychedelic and plant-based food stocks were extremely oversold in 2022. I'm tracking 12 microcap stocks that might bounce back with major returns - dare I say "multi-bagger" returns.